Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ERAS |
---|---|---|
09:32 ET | 6699 | 2.09 |
09:34 ET | 4400 | 2.1 |
09:36 ET | 5942 | 2.06 |
09:38 ET | 900 | 2.08 |
09:39 ET | 5395 | 2.1 |
09:41 ET | 15380 | 2.14 |
09:43 ET | 6384 | 2.1389 |
09:45 ET | 25278 | 2.135 |
09:48 ET | 7290 | 2.13 |
09:50 ET | 7082 | 2.13 |
09:52 ET | 2776 | 2.15 |
09:54 ET | 5757 | 2.15 |
09:56 ET | 4852 | 2.145 |
09:57 ET | 12066 | 2.115 |
09:59 ET | 3214 | 2.12 |
10:01 ET | 4778 | 2.12 |
10:03 ET | 7202 | 2.125 |
10:06 ET | 20552 | 2.095 |
10:08 ET | 5495 | 2.1 |
10:10 ET | 5866 | 2.1 |
10:12 ET | 5902 | 2.095 |
10:14 ET | 3696 | 2.095 |
10:15 ET | 10088 | 2.095 |
10:17 ET | 4100 | 2.095 |
10:19 ET | 3882 | 2.1 |
10:21 ET | 13210 | 2.09 |
10:24 ET | 5238 | 2.085 |
10:26 ET | 3495 | 2.09 |
10:28 ET | 9554 | 2.1 |
10:30 ET | 3495 | 2.1 |
10:32 ET | 8094 | 2.09 |
10:33 ET | 12307 | 2.075 |
10:35 ET | 6138 | 2.075 |
10:37 ET | 32353 | 2.06 |
10:39 ET | 4800 | 2.065 |
10:42 ET | 9981 | 2.055 |
10:44 ET | 16049 | 2.045 |
10:46 ET | 24109 | 2.045 |
10:48 ET | 2600 | 2.045 |
10:50 ET | 22710 | 2.05 |
10:51 ET | 2950 | 2.055 |
10:53 ET | 11445 | 2.055 |
10:55 ET | 11807 | 2.045 |
10:57 ET | 7389 | 2.045 |
11:00 ET | 30689 | 2.06 |
11:02 ET | 1961 | 2.07 |
11:04 ET | 7976 | 2.055 |
11:06 ET | 4548 | 2.055 |
11:08 ET | 15723 | 2.055 |
11:09 ET | 5193 | 2.05 |
11:11 ET | 7973 | 2.055 |
11:13 ET | 14192 | 2.045 |
11:15 ET | 8291 | 2.045 |
11:18 ET | 7829 | 2.045 |
11:20 ET | 21267 | 2.05 |
11:22 ET | 4110 | 2.06 |
11:24 ET | 7392 | 2.055 |
11:26 ET | 9071 | 2.05 |
11:27 ET | 7900 | 2.055 |
11:29 ET | 10437 | 2.055 |
11:31 ET | 8866 | 2.05 |
11:33 ET | 13057 | 2.05 |
11:36 ET | 15422 | 2.055 |
11:38 ET | 10450 | 2.055 |
11:40 ET | 8100 | 2.055 |
11:42 ET | 8500 | 2.055 |
11:44 ET | 15069 | 2.055 |
11:45 ET | 6293 | 2.05 |
11:47 ET | 9500 | 2.055 |
11:49 ET | 12091 | 2.055 |
11:51 ET | 19136 | 2.055 |
11:54 ET | 34917 | 2.065 |
11:56 ET | 1800 | 2.07 |
11:58 ET | 16633 | 2.075 |
12:00 ET | 3800 | 2.08 |
12:02 ET | 9866 | 2.085 |
12:03 ET | 8346 | 2.075 |
12:05 ET | 12024 | 2.07 |
12:07 ET | 10054 | 2.065 |
12:09 ET | 5000 | 2.065 |
12:12 ET | 10991 | 2.055 |
12:14 ET | 6100 | 2.055 |
12:16 ET | 5000 | 2.055 |
12:18 ET | 42346 | 2.06 |
12:20 ET | 11132 | 2.065 |
12:21 ET | 4281 | 2.07 |
12:23 ET | 11267 | 2.075 |
12:25 ET | 7607 | 2.075 |
12:27 ET | 8117 | 2.065 |
12:30 ET | 6100 | 2.065 |
12:32 ET | 5786 | 2.065 |
12:34 ET | 13941 | 2.055 |
12:36 ET | 8556 | 2.055 |
12:38 ET | 9400 | 2.055 |
12:39 ET | 8030 | 2.055 |
12:41 ET | 6328 | 2.055 |
12:43 ET | 6064 | 2.055 |
12:45 ET | 23662 | 2.045 |
12:48 ET | 13878 | 2.045 |
12:50 ET | 10235 | 2.035 |
12:52 ET | 7728 | 2.035 |
12:54 ET | 9969 | 2.035 |
12:56 ET | 15041 | 2.035 |
12:57 ET | 7522 | 2.04 |
12:59 ET | 12708 | 2.04 |
01:01 ET | 6164 | 2.035 |
01:03 ET | 7829 | 2.035 |
01:06 ET | 7517 | 2.035 |
01:08 ET | 9158 | 2.035 |
01:10 ET | 7529 | 2.04 |
01:12 ET | 7876 | 2.04 |
01:14 ET | 18045 | 2.025 |
01:15 ET | 9493 | 2.03 |
01:17 ET | 12403 | 2.03 |
01:19 ET | 9091 | 2.025 |
01:21 ET | 6983 | 2.025 |
01:24 ET | 10568 | 2.03 |
01:26 ET | 11319 | 2.03 |
01:28 ET | 9326 | 2.025 |
01:30 ET | 9883 | 2.03 |
01:32 ET | 7453 | 2.025 |
01:33 ET | 10367 | 2.03 |
01:35 ET | 8431 | 2.03 |
01:37 ET | 9149 | 2.025 |
01:39 ET | 9266 | 2.03 |
01:42 ET | 9567 | 2.03 |
01:44 ET | 9095 | 2.03 |
01:46 ET | 17897 | 2.025 |
01:48 ET | 17342 | 2.025 |
01:50 ET | 7148 | 2.025 |
01:51 ET | 28606 | 2.015 |
01:53 ET | 7623 | 2.02 |
01:55 ET | 8439 | 2.015 |
01:57 ET | 6484 | 2.015 |
02:00 ET | 37846 | 2.03 |
02:02 ET | 8374 | 2.03 |
02:04 ET | 21775 | 2.04 |
02:06 ET | 8370 | 2.04 |
02:08 ET | 31453 | 2.05 |
02:09 ET | 9396 | 2.055 |
02:11 ET | 5623 | 2.055 |
02:13 ET | 7941 | 2.055 |
02:15 ET | 15312 | 2.055 |
02:18 ET | 28328 | 2.055 |
02:20 ET | 6900 | 2.055 |
02:22 ET | 52020 | 2.055 |
02:24 ET | 6446 | 2.055 |
02:26 ET | 13435 | 2.06 |
02:27 ET | 14476 | 2.06 |
02:29 ET | 14204 | 2.06 |
02:31 ET | 14573 | 2.06 |
02:33 ET | 3745 | 2.07 |
02:36 ET | 11327 | 2.08 |
02:38 ET | 7299 | 2.08 |
02:40 ET | 6356 | 2.08 |
02:42 ET | 8233 | 2.08 |
02:44 ET | 7174 | 2.08 |
02:45 ET | 9453 | 2.07 |
02:47 ET | 5700 | 2.07 |
02:49 ET | 12112 | 2.075 |
02:51 ET | 40974 | 2.075 |
02:54 ET | 21131 | 2.09 |
02:56 ET | 10763 | 2.1 |
02:58 ET | 24089 | 2.11 |
03:00 ET | 5445 | 2.11 |
03:02 ET | 7918 | 2.11 |
03:03 ET | 32662 | 2.115 |
03:05 ET | 193854 | 2.105 |
03:07 ET | 175302 | 2.11 |
03:09 ET | 5248 | 2.11 |
03:12 ET | 8232 | 2.11 |
03:14 ET | 5525 | 2.11 |
03:16 ET | 13286 | 2.105 |
03:18 ET | 6600 | 2.105 |
03:20 ET | 8466 | 2.1 |
03:21 ET | 32369 | 2.105 |
03:23 ET | 8700 | 2.105 |
03:25 ET | 10560 | 2.1 |
03:27 ET | 6125 | 2.105 |
03:30 ET | 10709 | 2.105 |
03:32 ET | 9601 | 2.11 |
03:34 ET | 8700 | 2.1 |
03:36 ET | 7496 | 2.105 |
03:38 ET | 9100 | 2.105 |
03:39 ET | 72046 | 2.13 |
03:41 ET | 36768 | 2.16 |
03:43 ET | 16780 | 2.16 |
03:45 ET | 23915 | 2.18 |
03:48 ET | 15942 | 2.18 |
03:50 ET | 43128 | 2.21 |
03:52 ET | 11096 | 2.21 |
03:54 ET | 8024 | 2.21 |
03:56 ET | 75550 | 2.23 |
03:57 ET | 102999 | 2.215 |
03:59 ET | 125535 | 2.2 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Erasca Inc | 495.0M | -2.6x | --- |
Astria Therapeutics Inc | 495.3M | -3.9x | --- |
Allogene Therapeutics Inc | 500.1M | -1.3x | --- |
Kalvista Pharmaceuticals Inc | 487.3M | -3.6x | --- |
Mind Medicine (MindMed) Inc | 508.1M | -2.5x | --- |
Third Harmonic Bio Inc | 513.5M | -16.8x | --- |
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $495.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 238.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.84 |
Book Value | $2.10 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.